Amit Goyal
Gastroenterology · San Antonio, TXNPI 1225003676
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 137 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AbbVie at 26.7% of the total. That places this record below the midpoint for gastroenterology clinicians in TX, where the typical reported total is $3,104.
Across 137 payments — averaging $25.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$946
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$305
- Phathom Pharmaceuticals, Inc.$297
- Intercept Pharmaceuticals, Inc.$285
- Shockwave Medical, Inc$208
- Sanofi$169
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,539100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 52 | $946 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $305 |
| Phathom Pharmaceuticals, Inc. | 11 | $297 |
| Intercept Pharmaceuticals, Inc. | 13 | $285 |
| Shockwave Medical, Inc | 1 | $208 |
| Sanofi | 6 | $169 |
| Ardelyx, Inc. | 4 | $168 |
| Boston Scientific | 2 | $159 |
| Pfizer | 3 | $138 |
| Ipsen Biopharmaceuticals, Inc | 3 | $129 |
| Evoke Pharma, Inc. | 1 | $125 |
| Johnson & Johnson | 5 | $104 |
| AstraZeneca | 1 | $71 |
| Aimmune Therapeutics, Inc. | 4 | $66 |
| Bristol Myers Squibb | 3 | $45 |
| Ironwood Pharmaceuticals, Inc | 2 | $43 |
| Madrigal Pharmaceuticals | 2 | $43 |
| Echosens North America, Inc. | 1 | $40 |
| Ferring Pharmaceuticals Inc. | 2 | $26 |
| Shionogi Inc | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Gilead | 1 | $19 |
| QOL Medical, LLC | 1 | $19 |
| Organon | 2 | $18 |
| Olympus America Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
| AMAG Pharmaceuticals, Inc. | 1 | $15 |
| Abbott | 1 | $14 |
| Redhill Biopharma Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,547 in reported general payments places this provider in the 50th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcalivaObeticholic Acid | 19 | $170,526 |
| LinzessLinaclotide | 149 | $121,176 |
| XifaxanRifaximin | 28 | $90,628 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 127 | $20,936 |
| VemlidyTenofovir Alafenamide | 12 | $17,395 |
| Dexlansoprazole DrDexlansoprazole | 49 | $14,757 |
| Pantoprazole Sodium | 799 | $10,986 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 54 | $7,654 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 42 | $6,851 |
| Mesalamine | 15 | $6,354 |
| Esomeprazole Magnesium | 63 | $5,433 |
| Omeprazole | 251 | $5,369 |
| Cholestyramine LightCholestyramine | 35 | $4,848 |
| Sucralfate | 38 | $4,040 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 227 | $3,690 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Intercept Pharmaceuticals, Inc.Ocaliva | $285 | $170,52619 claims |
| AbbVieLinzess | $946 | $121,176149 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu | $305 | $98,28382 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $26 | $20,936127 claims |
| GileadVemlidy | $19 | $17,39512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,350 gastroenterology providers in Texas.
Other gastroenterology in San Antonio
- Eric LawitzSan Antonio$776K
- Charles RandallSan Antonio$749K
- Sandeep PatelSan Antonio$292K
- John FordtranDallas$9.9M
- Michael BrownDallas$5.5M
- Bincy AbrahamHouston$1.6M
- Mazen NoureddinHouston$1.5M
- Stephen PappasHouston$1.4M
- Anish PatelFort Sam Houston$1.3M
- Timothy RitterSouthlake$961K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.